Inclusion Criteria:
- Histologically confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in
tumor tissue and willingness to provide archival/fresh samples at screening for
central MTAP status confirmation.
- Advanced or metastatic NSCLC not amenable to curative therapies after progression on
prior therapies at the time of enrollment (based on the American Joint Committee on
Cancer, Ninth Edition).
- At least 1 measurable lesion as per RECIST v1.1.
- Documented radiographic disease progression on or after the most recent line of
treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Participant must be ≥ 18 years of age (or the legal age of consent in the
jurisdiction in which the study is taking place) at the time of signing the ICF.
- Capability to swallow tablets intact (without chewing or crushing).
Exclusion Criteria:
- Active brain metastases or carcinomatous meningitis.
- History of gastrointestinal disease or other gastrointestinal conditions (eg,
uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of
study treatment or result in inability to swallow oral medications.
- Prior treatment with a PRMT5 or MAT2A inhibitor.
- Known severe hypersensitivity to study treatment and/or any of its excipients.
- Other protocol-defined inclusion/exclusion criteria apply.
